Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share from the same period last year. The company reported quarterly sales of $15.048 million which beat the analyst consensus estimate of $14.793 million by 1.72 percent. This is a 9.50 percent decrease over sales of $16.627 million the same period last year.